United States Neuromodulation Market Growth, Demand and Challenges of the Key Industry Players 2024-32

1
United States Neuromodulation Market Research and
Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "United States Neuromodulation Market
  Industry Trends, Share, Size, Growth, Opportunity
  and Forecast 2024-2032," the United States
  neuromodulation market size is projected to
  exhibit a growth rate (CAGR) of 11.50 during
  2024-2032.
• Neuromodulation is a medical technique that
  involves the alteration of nerve activity through
  the delivery of electrical or pharmaceutical
  agents directly to a target area. This approach
  is used to treat various neurological conditions
  and chronic pain disorders by modulating the
  nervous systems activity. Common methods include
  deep brain stimulation (DBS), spinal cord
  stimulation (SCS), and vagus nerve stimulation
  (VNS).
• These techniques involve implanting a device that
  delivers controlled electrical impulses to
  specific nerves or brain regions, thereby
  altering abnormal signals and restoring normal
  function. Neuromodulation is used to manage
  conditions such as Parkinsons disease, epilepsy,
  depression, and chronic pain. Its precision and
  minimally invasive nature offer significant
  benefits over traditional treatments, providing
  patients with improved symptom control and
  quality of life. The field continues to evolve
  with advancements in technology, expanding its
  potential applications and efficacy.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/united-states-neuromodu
  lation-market/requestsample

4
Report Description

• United States Neuromodulation Market Trends
• The rising incidence of neurological conditions
  such as Parkinsons disease, epilepsy, chronic
  pain, and depression is a significant driver. As
  the population ages, the prevalence of these
  disorders is expected to increase, fueling demand
  for neuromodulation therapies that offer
  effective symptom management. Continuous
  innovations in neuromodulation devices, such as
  enhanced battery life, miniaturization, and
  improved precision of electrical stimulation, are
  making these treatments more effective and
  accessible. Developments in wireless technology
  and rechargeable implants also contribute to the
  markets growth by improving patient convenience
  and compliance. The increasing awareness among
  both patients and healthcare providers about the
  benefits of neuromodulation therapies is driving
  higher adoption rates.
• These therapies offer targeted treatment options
  with fewer side effects compared to traditional
  pharmaceutical approaches, making them attractive
  alternatives. With the opioid crisis highlighting
  the need for alternative pain management
  strategies, neuromodulation therapies such as
  spinal cord stimulation are gaining traction as
  effective, non-opioid solutions for chronic pain.
  Improved reimbursement frameworks and insurance
  coverage for neuromodulation procedures are
  making these treatments more affordable for
  patients, thereby boosting market growth.
  Significant investments in research and
  development by both public and private sectors
  are leading to new product launches and expanding
  the therapeutic applications of neuromodulation.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/united-states-neuromodu
  lation-market

5
Report Segmentation

• Technology Insights
• Internal Neuromodulation
• Spinal Cord Stimulation (SCS)
• Deep Brain Stimulation (DBS)
• Vagus Nerve Stimulation (VNS)
• Sacral Nerve Stimulation (SNS)
• Gastric Electrical Stimulation (GES)
• External Neuromodulation
• Transcutaneous Electrical Nerve Stimulation
  (TENS)
• Transcranial Magnetic Stimulation (TMS)
• Others
•  
• Biomaterial Insights
• Metallic Biomaterials
• Polymeric Biomaterials

6
Report Segmentation

• Ceramic Biomaterials
• Application Insights
• Parkinson's Disease
• Epilepsy
• Depression
• Dystonia
• Pain Management
• Others
• Regional Insights
• Northeast
• Midwest
• South
• West

7
Key Questions Answered in the Report
8
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4 United
  States Neuromodulation Market - Introduction
• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence
• 5 United States Neuromodulation Market
  Landscape
• 5.1 Historical and Current Market Trends
  (2018-2023)
• 5.2 Market Forecast (2024-2032)
• 6 United States Neuromodulation Market -
  Breakup by Technology
• 6.1 Internal Neuromodulation
• 6.1.1 Overview
• 6.1.2 Historical and Current Market
  Trends (2018-2023)
• 6.1.3 Market Segmentation
• 6.1.3.1 Spinal Cord Stimulation (SCS)
• 6.1.3.2 Deep Brain Stimulation (DBS)
• 6.1.3.3 Vagus Nerve Stimulation (VNS)
• 6.1.3.4 Sacral Nerve Stimulation (SNS)
• 6.1.3.5 Gastric Electrical Stimulation
  (GES)
• 6.1.4 Market Forecast (2024-2032)     
   

9
Table of Contents

• 6.2 External Neuromodulation
• 6.2.1 Overview
• 6.2.2 Historical and Current Market
  Trends (2018-2023)
• 6.2.3 Market Segmentation
• 6.2.3.1 Transcutaneous Electrical
  Nerve Stimulation (TENS)
• 6.2.3.2 Transcranial Magnetic
  Stimulation (TMS)
• 6.2.3.3 Others
• 6.2.4 Market Forecast (2024-2032)
• 7 United States Neuromodulation Market -
  Breakup by Biomaterial
• 7.1 Metallic Biomaterials
• 7.1.1 Overview
• 7.1.2 Historical and Current Market
  Trends (2018-2023)
• 7.1.3 Market Forecast (2024-2032)
• 7.2 Polymeric Biomaterials
• 7.2.1 Overview
• 7.2.2 Historical and Current Market
  Trends (2018-2023)
• 7.2.3 Market Forecast (2024-2032)
• 7.3 Ceramic Biomaterials
• 7.3.1 Overview

10
Partial List of Clients
11
Partial List of Clients
12
Disclaimer

• 2024 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

13
Contact Us
Visit us at
https//www.imarcgroup.com
1-631-791-1145
sales_at_imarcgroup.com
Stay With Us